3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market from 2009-2015

The global ophthalmic pharmaceutical market will experience a declining growth rate during the period of 2009-2015. From an annual growth rate of in 2009, growth will decline to from 2012 to 2015 (Table 3.4, Table 3.5 and Figure 3.3). Generic competition in the leading area of the market, anti-glaucoma medications, will account for these decreased growth rates. Overall, the ophthalmic pharmaceutical market will increase in value from in 2009 to in 2015, corresponding to a CAGR of during this period.

3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market from 2016-2021?

Visiongain predicts that the ophthalmic pharmaceutical market will grow from in 2016, to reach by 2018. By 2021, revenues will have increased further to representing a CAGR of for the period 2009 to 2021. Increasing numbers of elderly people and the consequent escalating occurrence of ophthalmic disease – especially glaucoma, AMD and DR – will stimulate demand for ophthalmic drugs from 2016 to 2021. Certain currently-marketed products, most notably Lucentis, will expand in sales by meeting that demand. Additionally, the launch of novel products to treat dry AMD, DR and offer neuroprotective benefits for glaucoma patients will add further revenues to the market by better meeting those demands (Table 3.6, Table 3.7, Figure 3.4 and Figure 3.5).
4.1.9 Trusopt

Merck & Co.’s Trusopt (dorzolamide) is a topical carbonic anhydrase III inhibitor, indicated in the treatment of elevated intraocular pressure in glaucoma and ocular hypertension. It was launched in Japan in 1999. Trusopt was launched in combination with the beta-blocker Timoptic (timolol), for instances of glaucoma and ocular hypertension unresponsive to therapy with either agent alone, as Cosopt in the US in 1998.

Trusopt is formulated as an eyedrop ophthalmic solution, with the usual dose being one drop twice daily. Cosopt was first launched in the UK and the US, and is now marketed worldwide. Trusopt was the eighth-leading anti-glaucoma brand in 2009, with total revenues of (market share).

4.1.10 Combigan

Combigan (brimonidine 0.2% + timolol 0.5%) is a combination of Allergan’s Alphagan (brimonidine) with the beta-blocker timolol maleate. The product was first approved and launched in 2003 in Canada, and subsequently in Brazil in 2004. Combigan is indicated in the reduction of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers. The first EU launch was in the UK in April 2005. The product is now available in more than markets worldwide, including the US (FDA approval in October 2007). Combigan sales were in 2009 (market share).

4.1.11 Extravan/Duotrav

Extravan/Duotrav (travoprost 0.004%) + timolol 0.5%) is a fixed combination of the prostaglandin analogue travoprost with the Alcon’s timolol, a beta blocker developed for the treatment of glaucoma. It was first filed for approval in the US in January 2004. It was later approved
in Canada, Europe and various other markets. From 2006 it was
launched in Canada and across Europe. However, DuoTrav has still
not yet been approved in the US. Alcon received notification from the
FDA that it was approvable in September 2004, but further information
was requested by the FDA. In early 2008 it was filed for approval in
Japan and was recommended for approval in February 2010.
Extravan/Duotrav sales were [ ] in 2009 ( [ ] market share).

4.2 Anti-Glaucoma Market Forecasts, 2009-2021

4.2.1 Generic Competition Will Affect the Anti-
Glaucoma Market from 2009-2015

The global anti-glaucoma market will show a moderate increase in
growth during the period 2009 to 2012. Revenues will increase from
[ ] in 2009 to [ ] in 2010, visiongain predicts (Table 4.2,
Table 4.3 and Figure 4.2). Increasing numbers of elderly people, and
therefore glaucoma prevalence, will drive this modest growth.
Prostaglandin analogue/prostamide brands and combinations of these
with beta blockers will account for most of this growth, owing to their
superior efficacy and dosing schedules.

<table>
<thead>
<tr>
<th>Year</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Anti-Glaucoma Market ($m)</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>Growth (%)</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>CAGR (% from 2009)</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

Source: visiongain 2011